TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Open and Minimally Invasive Surgical Techniques in the Treatment of Degenerative One-level Stenosis of Lumbar Spine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* syndrome of mono- or polyradicular compression of the nerve roots with / without a reflex pain syndromes, caused by stenosis of one lumbar spine segment;~* intermittent claudication caused by stenosis of one lumbar spine segment;~* one-level spine stenosis in combination with local segment instability or degenerative spondylolisthesis at the same spine segment, requiring fusion in only one lumbar segment~Exclusion Criteria:~* bilateral foraminal lumbar spine stenosis;~* lumbar spine stenosis more than one-level;~* spondylolisthesis II degree and more;~* sagittal imbalance;~* fusion the same lumbar spine segment after surgery previously;~* other diseases of the spine, including trauma, tumor and inflammatory diseases of the lumbar spine, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Minimally invasive fusion (Type: EXPERIMENTAL): Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
- Open Fusion (Type: ACTIVE_COMPARATOR): Bilateral decompression, open fusion + screw fixation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previous pregnancy complicated with pre-eclampsia/eclampsia~* Singleton pregnancy~* Gestational age \>20 weeks \<34 weeks~* Protein excretion \< 300 mg/day~Exclusion Criteria:~* Multiple gestation~* Major fetal anomaly~* Pre-existing hypertension~* Pre-existing renal disease~* Diabetes~* Collagen vascular disease~* Cancer or strong family history of cancer in first degree relatives~* Preexisting maternal disease requiring medication

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 32 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or females with an age ≥ 18 years.~2. Subjects with histological- or cytological-confirmed, advanced cancer, who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists~   1. For Phase 1, only subjects HER2 or HER3 molecular/genetic alterations will be enrolled.~  2. For Phase 2a, subjects with one of the following tumor types will be enrolled:~   i. Urothelial cancer with HER2 or HER3 mutation ii. Biliary tract cancer with HER2 or HER3 mutation iii. Breast cancer with HER2 or HER3 mutation iv. Breast cancer with HER2 amplification or overexpression v. NSCLC with HER2 or HER3 mutation vi. CRC with HER2 mutation or amplification vii. Other tumors with HER2 mutation/amplification/overexpression or HER3 mutation (gastric/GEJ, endometrial).~3. At least 1 measurable lesion for solid tumor~4. Is able to take medications orally (e.g., no feeding tube).~5. Able to agree to and sign informed consent and to comply with the protocol~6. Has adequate organ function~Exclusion Criteria:~1. Has a serious illness or medical condition(s)~2. Has received treatment with any proscribed treatments within specified time frames prior to study drug administration~3. Impaired cardiac function or clinically significant cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS0728 (Type: EXPERIMENTAL): Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: StepRite Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral total knee arthroplasty performed under regional (spinal +/- epidural) or general anesthesia. Surgical approach via an anterior 4-6 inch incision and utilizing a medial parapatellar arthrotomy incision. Posterior stabilized total knee arthroplasty decision.~* Age 55-75 yr. old~* BMI \<35~Exclusion Criteria:~* History of neuromuscular disorder (e.g. Parkinson's, Polio, or stroke).~* Contralateral degenerative joint disease requiring a TKA.~* Pregnancy

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Device (Type: EXPERIMENTAL): Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
- Usual and customary care (Type: NO_INTERVENTION): Participants in this arm will undergo usual care and will not be issued with the StepRite device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Study of Brain Tumors in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary intracranial central nervous system tumor~  * Medulloblastoma~ * Primitive neuroectodermal tumor~ * Atypical teratoid/rhabdoid tumor~ * Choroid plexus carcinoma~* Potential enrollment on PBTC-001 therapeutic protocol~PATIENT CHARACTERISTICS:~Age:~* Under 3~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Prior steroids allowed~Radiotherapy:~* No prior radiotherapy~Surgery:~* Not specified~Other:~* No concurrent investigational agents

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Muscle Strength in Patients With NMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of neuromuscular disease~* Clinical evidence of impaired pulmonary function~Exclusion Criteria:~* Above or below age range~* No clinical evidence of impaired pulmonary function~* No diagnosis of a neuromusuclar disease~* Presence of an acute illness at time of study~* Participating in other research studies involving investigational drugs~* Diagnosis of a primary pulmonary disease~* Use of tobacco products

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exercise (Type: EXPERIMENTAL): Threshold PEP or IMT device Phillips-Respironics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients who have:~* Been admitted to the medical unit on 7 West at St. Luke's Hospital (Duluth, MN)~* Been prescribed a systemic antibiotic of any kind (administered by oral or parenteral route), but have not yet started the regimen~* Consented to be randomized and take part in the study and are adults greater than 19 years of age~Exclusion Criteria:~Patients who are/have:~* Tube feeding~* Undergoing dialysis and other renal treatment~* An existing C. difficile infection~* A recent history of C. difficile infection (within the last 3 months)~* A recent history of antibiotic use (within the last 3 months)~* Inflammatory bowel disease, Crohn's disease, or other chronic gastrointestinal syndrome~* A history of acquired of genetic immunodeficiencies; active, acute or chronic serious infections (i.e., viral hepatitis, HIV/AIDS), or autoimmune disorders~* Undergoing gastrointestinal surgery, radiation, or cytotoxic chemotherapy~* Allergy to milk protein

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: NO_INTERVENTION): Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
- Group B (Type: ACTIVE_COMPARATOR): Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
- Group C (Type: ACTIVE_COMPARATOR): Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran~* 18-65 years of age~* Moderate-severity OSA \[\[Apnea-hypopnea index (AHI) 15 at screening\]~* Overweight/obese~* Physically inactive~* BMI 28~* Sedentary lifestyle (planned activity for purpose of health \< 2 days/week)~* Stable weight Not engaged in weight loss study or program~* Stable medications Medications for thyroid, cholesterol, blood pressure, and other conditions at same dose for 2 months~* Capable of signing consent and willing to provide informed consent and accept randomization assignment~Exclusion Criteria:~* Current OSA treatment Current use of continuous positive airway pressure (PAP), dental devices, etc. for OSA treatment. Past PAP or oral appliances are not exclusions if discontinued 2 months before study~* Significant disease: known or signs/symptoms of cardiovascular, metabolic, or pulmonary disease~* Uncontrolled hypertension: Blood pressure \> 159/99 mmHg~* Unable to exercise: musculoskeletal, orthopedic, neuromuscular, or other conditions that do not allow exercise or where exercise is contraindicated~* Any accident attributable to sleepiness in previous 3 years~* Current pregnancy/planning to become pregnant~* Clinically judged unsuitable as evaluated by supervising medical physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Exercise (Type: EXPERIMENTAL): 16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
- Weight Loss (Type: EXPERIMENTAL): 16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
- Exercise + Weight Loss (Type: EXPERIMENTAL): Combined components of the exercise and weight loss treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching Service at 855-56-LUPUS. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.~Note: Subjects \> 16 are eligible for enrollment at selected centers~Inclusion Criteria:~* Potential subjects must have active lupus nephritis~* Biopsy within 12 months prior to screening visit indicating active Class 3 or 4 proliferative lupus glomerulonephritis (lupus effecting your kidney)~* Urine protein creatinine ratio (UPCR) ≥ 1 at Screening~* Serum creatinine ≤ 3 mg/dL (ie, ≤ 265 micromol/L)~* There must also be evidence of active disease within 3 months of Screening, based on at least one of the following:~  * Worsening of lupus nephritis OR~ * UPCR ≥ 3 at Screening OR~ * Active urine sediment OR~ * Biopsy within 3 months prior to screening visit indicating active Class 3 or Class 4 active proliferative lupus glomerulonephritis~Inclusion Criteria for the Long-Term Extension Period:~* Signed Written Informed Consent~* Subjects who achieve a complete or partial renal response after completing 2 years of double-blind treatment~Exclusion Criteria:~* Systemic Lupus Erythematosus (SLE) must be the primary/main autoimmune diagnosis~* Current symptoms of severe, progressive, or uncontrolled non-SLE related renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, or other concomitant medical conditions that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study~* Significant active Central nervous system (CNS) lupus with the exception of fatigue or mild stable cognitive~* Subjects who are diagnosed as end-stage renal disease or whose kidney damage is too significant and irreversible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-188667 + Mycophenolate mofetil + Prednisone (Type: EXPERIMENTAL): BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
- Placebo + Mycophenolate mofetil + Prednisone (Type: PLACEBO_COMPARATOR): Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Salvage Cryotherapy in Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Read \& understand informed consent related to this study including consenting and HIPPA authorization~* Undergone salvage cryotherapy of the prostate for recurrent prostate cancer~Exclusion Criteria:~* Patients who underwent radical prostatectomy as their primary therapy or other significant surgery (except prostatic biopsy)~* Patients with clinically confirmed distant metastasis (unless deemed beneficial by the treating physician)~* Any previous major rectal surgery~* Clinically significant lower urinary tract or rectal anomalies~* Existing urethral, rectal, or bladder fistulae

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Observational (Type: None): Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the hospital for a COPD exacerbation~* FEV1 less than 60% of predicted level~* At least 10 pack years of smoking~Exclusion Criteria:~* Any uncontrolled systemic disease~* Known hypersensitivity to zileuton~* Asthma~* Lobar pneumonia or pulmonary edema~* Interstitial lung disease~* Medical condition that is likely to limit survival to less than 30 days at the time of study entry~* History of liver disease~* Current use of theophylline~* Participation in another clinical trial in the COPD Clinical Research Network~* Incarceration~* Institutionalization~* Pregnant~* History of a suicide attempt~* Prior inpatient admission for a psychiatric disorder~* Bipolar disorder~'

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zileuton (Type: ACTIVE_COMPARATOR): Zileuton (Zyflo, 600 mg 4 times a day)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participation in the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)~2. Written informed consent~Exclusion Criteria:~1. Patients who do not meet the inclusion criterial of the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Afatinib (Type: EXPERIMENTAL): Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
- Arm B: Pemetrexed (Type: EXPERIMENTAL): Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Treatment of Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Be Age ≥ 18 years~2. Have a documented diagnosis of chronic neuropathic pain~3. In the opinion of the investigator, be considered at the time of screening a likely candidate for surgical treatment of their neuropathic pain according to institutional standard of care.~4. Be willing to participate in data collection and all follow-up assessments throughout and for the entire duration of follow-up~Exclusion Criteria:~1. Subjects who, in the opinion of the investigator, have not or likely will not complete the required follow-up assessments.~2. Subjects who are currently enrolled in another clinical trial;~3. Subjects who have undergone previous surgical treatment of pain from symptomatic neuroma in the target nerve(s);~4. Subjects who are undergoing treatment(s)/intervention(s) for other condition(s) which, in the opinion of the investigator, may confound assessment of pain or interfere with the study measurements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery (Type: None): Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
- Non-surgery (Type: None): Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues